Dr. Cindy Okada Scharfen, MD

Dr. Scharfen practices at Providence Santa Rosa Memorial Hospital in Santa Rosa, California, part of Providence Health & Services.

Dr. Scharfen's NPI, 1861582322, was assigned on October 13, 2006. Dr. Scharfen graduated from UCSF School of Medicine in 1988. Dr. Scharfen's California license number on file is G67266.

Dr. Scharfen's primary practice is Providence Santa Rosa Memorial Hospital, at 1165 Montgomery Dr, Santa Rosa, CA 95405 in Sonoma County. The practice phone is (707) 525-5300.

Dr. Scharfen's primary practice is Providence Santa Rosa Memorial Hospital in Santa Rosa, California, part of Providence Health & Services. Dr. Scharfen is also affiliated with Sonoma Valley Hospital. The medical group on file is St. Jude Heritage Medical Group. Dmand AI also links Dr. Scharfen to 4 more group practices and clinics and 3 medical groups, each named with a free account.

Dmand AI tracks the electronic health record (EHR) system at each site where Dr. Scharfen practices, 6 sites in all. Vendor and product names are available with a free account.

Radiation oncology is Dr. Scharfen's primary specialty in the NPI Registry, under taxonomy code 2085R0001X. Dr. Scharfen is board certified in radiation oncology by the American Board of Radiology. Dr. Scharfen has a license on file in California.

Dmand AI lists bone cancer radiation, brain cancer radiation, brain tumor radiation, breast cancer radiation, cancer radiation-upper GI, colorectal cancer radiation, head & neck cancer radiation and lung cancer radiation among the conditions Dr. Scharfen treats.

CMS data shows 2,881 Medicare services from Dr. Scharfen across 18 procedure codes in 2024, for 390 Medicare patients. Medicare paid $230,418 for them. Every service was in an office.

CMS counts 390 Medicare patients who saw Dr. Scharfen in 2024. The largest group is 65 to 74, with 174 patients. 75% of them have cancer, and 70% have high blood pressure. 23% are also on Medicaid. Their average risk score is 1.89, where 1.00 is the Medicare average, so they are sicker than most Medicare patients.

Across all payers, Dmand AI patient panel data puts Dr. Scharfen's median patient age at 76, with 41% women.

In 2024, Dr. Scharfen wrote 150 Medicare Part D claims for 83 patients. 77% of them were for generic drugs. CMS names the drug for 56 of them, across 2 drugs with 11 or more claims each, at $485 in total drug cost. In 2023, CMS named 39 claims across 2 drugs.

Dr. Scharfen accepts Medicare assignment, so Medicare's approved amount is taken as full payment. CMS lists Dr. Scharfen as offering telehealth.

Dmand AI links 4 papers to Dr. Scharfen. The most frequent topics are Brachytherapy, Brain Neoplasms and Glioblastoma. Dr. Scharfen has published most often in Int J Radiat Oncol Biol Phys. Dr. Scharfen's most frequent co-authors are Philip H. Gutin, MD, Michael Prados, MD and Patricia K. Sneed, MD.

CMS Open Payments shows 294 general payments to Dr. Scharfen from 53 drug and device companies from 2016 to 2025. Food and beverage make up the largest share, 99% of the total. Merck Sharp & Dohme Corporation paid the most, $622.

Dmand AI lists 1 award for Dr. Scharfen, most recently Regional Top Doctor in 2014.

Dr. Scharfen graduated from UCSF School of Medicine in 1988.

Dr. Scharfen is in network with 13 carriers, including Aetna, Elevance and Blue Cross Blue Shield of Michigan. PPO plans come from the most carriers, 9. Check the plan with the practice before a visit.